Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events

por Partridge, Wesley, Burel, Sebastien A., Ferng, Annie, Xia, Shuting, Kwoh, T. Jesse, Henry, Scott P., Baker, Brenda F.
Publicado 2023

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers

por Crooke, Stanley T, Baker, Brenda F, Kwoh, T Jesse, Cheng, Wei, Schulz, Dan J, Xia, Shuting, Salgado, Nelson, Bui, Huynh-Hoa, Hart, Christopher E, Burel, Sebastien A, Younis, Husam S, Geary, Richard S, Henry, Scott P, Bhanot, Sanjay
Publicado 2016

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts

por Burel, Sebastien A., Hart, Christopher E., Cauntay, Patrick, Hsiao, Jill, Machemer, Todd, Katz, Melanie, Watt, Andy, Bui, Huynh-hoa, Younis, Husam, Sabripour, Mahyar, Freier, Susan M., Hung, Gene, Dan, Amy, Prakash, T.P., Seth, Punit P., Swayze, Eric E., Bennett, C. Frank, Crooke, Stanley T., Henry, Scott P.
Publicado 2016

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides

por Anderson, Brooke A, Freestone, Graeme C, Low, Audrey, De-Hoyos, Cheryl L, III, William J Drury, Østergaard, Michael E, Migawa, Michael T, Fazio, Michael, Wan, W Brad, Berdeja, Andres, Scandalis, Eli, Burel, Sebastien A, Vickers, Timothy A, Crooke, Stanley T, Swayze, Eric E, Liang, Xuehai, Seth, Punit P
Publicado 2021